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Summary Mycobacterium celatum, a slow-growing acid-fast bacillus, is an uncommon cause of
human infection, mainly occurring in patients with AIDS. Rarely, infections restricted to the lung
and lymph nodes have been reported in immunocompetent hosts. We report herein a case of M.
celatum pulmonary infection that mimicked pulmonary tuberculosis in a patient with ankylosing
spondylitis. The literature was reviewed and clinical features of eight HIV-negative patients with
M. celatum infection are discussed. The clinical presentation of M. celatum is indistinguishable
from tuberculosis, especially in patients with a previous history of pulmonary tuberculosis. Proper
treatment depends on a definitive identification of this pathogen, which requires 16S rDNA
sequencing or mycolic acid high performance liquid chromatography analysis.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Mycobacterium celatum, a slow-growing acid-fast bacillus,
was proposed as a new species in 1993.1 The biochemical
characteristics of this organism are similar to those of Myco-
bacterium xenopi and members of the Mycobacterium avium
complex.1 M. celatum is an uncommon cause of human
infection and most infections caused by this organism occur
in people with AIDS.2,3 It can cause disseminated disease in* Corresponding author. Tel.: +886 2 23123456x65355.
E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).
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doi:10.1016/j.ijid.2008.12.014patients with AIDS,4,5 but in immunocompetent patients, M.
celatum infection may be restricted to the lung or lymph
nodes.2,6—10 We describe herein a case of M. celatum pul-
monary infection mimicking pulmonary tuberculosis (TB) in a
patient with ankylosing spondylitis, and review the reported
cases of M. celatum infections in non-HIV infected patients.
Case report
A 50-year-old man developed a cough with blood-tinged spu-
tum, with onset 3—4 days before presentation . His medical
history was unremarkable except for previous pulmonary TBPublished by Elsevier Ltd. All rights reserved.
Table 1 Clinical features of eight HIV-negative patients with Mycobacterium celatum infection
Case No.
[Ref.]
Year Age (years) Sex Country Underlying
disease
Presentation Chest radiograph Clinical diagnosis Treatment Outcome
1 [6] 1994 15 months M Germany None Painless submandibular
lymphadenopathy
Normal Lymphadenitis Complete
excision
No recurrence
2 [7] 1998 73 F Germany Diabetes
mellitus
Nonproductive cough,
fever, respiratory
failure
LUL cavity Pulmonary
infection
Cip, Cla,
Pyr, Eth
Died after
treatment for
6 weeks
3 [8] 2001 61 M Netherlands None General malaise,
productive cough,
weight loss
RUL infiltrate
with extensive
cavities
Pulmonary
infection
Eth, Cla, Rib Improvement
4 [9] 2003 63 F Italy Pulmonary
tuberculosis,
hypertensive
cardiovascular
disease
Fever, night sweats RUL cavity and
nodular
infiltration
Pulmonary
infection
Inh, Eth, Cla Cure
5 [10] 2003 79 M Ireland TB
lymphadenitis,
COPD
Dyspnea, night sweats,
general malaise,
weight loss, fever
RUL
consolidation
Pulmonary
infection
Rif, Eth, Cla Improvement
6 [2] 2004 22 months F USA None Painless submandibular
lymphadenopathy
Normal Lymphadenitis Incomplete
excision + Azi
Regression of
lymphadenopathy
7 [2] 2004 37 F USA Right lung
transplant
recipient
for LAM
Productive cough,
dyspnea
LLL nodular,
right lung diffuse
infiltrates
Pulmonary
infection
Cla, Cip Progress
Present
case
2008 50 M Taiwan Pulmonary
tuberculosis
Cough, hemoptysis RUL infiltrates Pulmonary
infection
Cip, Cla Improvement
Azi, azithromycin; Cip, ciprofloxacin; Cla, clarithromycin; COPD, chronic obstructive pulmonary disease; Eth, ethambutol; Inh, isoniazid; LAM, lymphangioleiomyomatosis; LLL, left lower lobe;
LUL, left upper lobe; Pyr, pyrazinamide; Rib, rifabutin; Rif, rifampin; RUL, right upper lobe; TB, tuberculosis.
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Mycobacterium celatum pulmonary infection e461status after a complete course of anti-TB treatment and
ankylosing spondylitis without treatment. He had not experi-
enced fever, fatigue, anorexia, regional adenopathy, gastro-
intestinal symptoms, or weight changes during the course of
this illness. Physical examinationwas unremarkable except for
coarse crackles in the right lung. Laboratory examination
revealed a white blood cell count of 8.14  109/l, with 62%
neutrophils and 26.2% lymphocytes. Chest X-ray showed a
pulmonary infiltration in the right middle lobe and a calcifica-
tion plaque at the right costophrenic angle. Three consecutive
sputum samples were positive for acid-fast bacilli. A reactiva-
tion of tuberculosis was assumed, and anti-TB therapy with
isoniazid, rifampin, and ethambutol was started.Twenty-eight
days later, culture of sputum grew Mycobacterium spp. The
isolate was a slowly growing scotochromogen (producing a
weak yellow pigment in the dark at 45 8C) andwas negative for
niacin accumulation, nitrate reduction, hydrolysis of Tween
80, and arylsulfatase activity (3 days). The isolate was further
identified as M. celatum by partial 16S rRNA gene (98%)
analysis (accession number AY215233).9 These findings met
theAmericanThoracic Society criteria for thediagnosis of non-
tuberculous mycobacterial disease,11 and indicated that M.
celatum caused the pulmonary infection. Chemotherapy was
changed to clarithromycin (500 mg every 12 hours) and cipro-
floxacin (500 mg every 12 hours), and the patient’s symptoms
and radiographic findings improved thereafter.
Discussion
M. celatum has been established as a pathogen causing
infection mainly in AIDS patients,2—5 and its role in disease
among other populations is rarely described. Here we have
described the first reported case of isolation of this organism
in Taiwan. Our review of the literature also revealed seven
previously reported cases with clinical details of M. celatum
infection in HIV-negative patients.2,6—10 The clinical features
of these seven cases together with the present case are
summarized in Table 1.
Patient age ranged from 13 months to 79 years and four
were male. Two patients had a history of pulmonary TB and
another patient had TB lymphadenitis. One patient was a
lung transplant recipient. No obvious immune disorder
was detected in three patients. Two children presented
with painless lymphadenopathy and the other six adults
had pulmonary infection. Among the six patients with
pulmonary infection, cough was the most common
symptom, followed by fever, night sweating, and weight
loss. Upper lobes were the most commonly involved lung
fields.
In summary, the presentation of M. celatum pulmonary
infection, including clinicalmanifestations and radiographic
findings, mimics pulmonary TB. However, the identification
of M. celatum is difficult in routine practice, and definitive
identification of the clinical isolates requires 16S rDNA
sequencing or mycolic acid high performance liquid chro-
matography (HPLC) analysis.2 Therefore, the clinician
should remain alert to M. celatum as a possible cause of
pulmonary infection and lymphadenitis in non-HIV infected
patients and the need for advanced technology for diagnos-
tic accuracy.
Susceptibility testing of M. celatum is not standardized
but the organism is generally susceptible to azithromycin,clarithromycin, and ciprofloxacin.2 In an animal model,
clarithromycin, azithromycin, and ethambutol were shown
to be the most active agents.12 The antimicrobial manage-
ment of M. celatum infection varied among these eight
reported cases. In the cases of the two children with
cervical lymphadenitis, conservative neck dissection was
performed in one and the other received incomplete exci-
sion and 6 months of azithromycin. Both of these children
had a favorable outcome. All six patients with M. celatum
pulmonary infection received combination therapy includ-
ing clarithromycin and ethambutol or ciprofloxacin. Four of
the six patients had clinical improvement, one patient had
radiographic worsening after 3 months of treatment, and
one made a temporary improvement but died 6 weeks after
starting treatment. Although the case data are very lim-
ited, clarithromycin-based chemotherapy resulted in clin-
ical improvement in most reported cases of M. celatum
infection.
In conclusion, M. celatum can cause cervical adenitis in
children and pulmonary infection in non-HIV infected
patients. Because the clinical presentation is indistinguish-
able from Mycobacterium tuberculosis infection, precise
identification of the causative species is imperative to avoid
missing this infrequent pathogen. Macrolide-based therapy
may lead to a better outcome.
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